Medtronic and Covidien are nearing the finish line of their pending $43 billion merger as Medtronic shareholders voted on Tuesday to approve the deal, following in the footsteps of a similar vote from Covidien shareholders.
Venture-backed medical device and diagnostics companies are benefiting from a groundswell of investor interest in life sciences that has been spearheaded by great biotech returns for the last several years.
Fujifilm has completed its acquisition of Kalon Biotherapeutics, a contract manufacturer with a focus on vaccines.
Eli Lilly started the new year by announcing it has closed its $5.4 billion acquisition of Novartis Animal Health, in the process expanding its Elanco animal health unit to 17 manufacturing sites and 14 R&D centers.
Bloomberg reports that Stryker is planning to offer a premium for the U.K.'s S&N of about 30%. Currently, the target has a valuation of about $16.3 billion. The sources say a tax inversion is not planned. However, one of the unnamed sources also says Stryker's management could change its mind.
2014 was the year for medical device M&A activity. We don't expect to see med tech merger mania slow anytime soon, as the underlying motivations to improve growth rates, save on taxes and buy into new technology haven't changed. But there just aren't very many big medical device companies and that in itself limits the deal potential going forward.
Roche snatched up DNA sequencing outfit Bina Technologies for an undisclosed sum, continuing its M&A winning streak and expanding its diagnostics footprint.
Contract researcher KCR is dialing up its presence in Ukraine, buying out a competitor's whole clinical portfolio and doubling down on a country it believes is ripe for R&D growth.
Mobile medical apps are all the rage, but software is growing in importance in traditional medical devices too, as evidenced by Varian Medical Systems announcement that it will acquire Germany's MeVis Medical Solutions AG, a provider of software for cancer imaging.
Philips is shelling out $1.2 billion for San Diego devicemaker Volcano to gain ground in catheter-based imaging and beef up its offerings as it refocuses on its new healthcare business.